Walter V. Klemp - Jul 2, 2024 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Role: CEO and President, Director
Signature: /s/ Jonathan P. Foster by Power of Attorney
Stock symbol: MBRX
Transactions as of: Jul 2, 2024
Transactions value $: -$857
Form type: 4
Date filed: 7/5/2024, 05:01 PM
Previous filing: Jun 25, 2024
Next filing: Nov 6, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MBRX	Common Stock	Options Exercise		+982	+1.74%		57.3K	Jul 2, 2024	Direct	F1
transaction	MBRX	Common Stock	Tax liability	-$857	-240	-0.42%	$3.57	57K	Jul 2, 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MBRX	Restricted Stock Units	Options Exercise	$0	-982	-0.86%	$0.00	113K	Jul 2, 2024	Common Stock	982		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
F3	On July 2, 2020, the reporting person was granted 3,926 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.